Mei Cheng

5.0k total citations · 1 hit paper
20 papers, 1.1k citations indexed

About

Mei Cheng is a scholar working on Cardiology and Cardiovascular Medicine, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Mei Cheng has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 8 papers in Genetics and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Mei Cheng's work include Chronic Lymphocytic Leukemia Research (8 papers), Heart Failure Treatment and Management (7 papers) and Cardiac electrophysiology and arrhythmias (6 papers). Mei Cheng is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Heart Failure Treatment and Management (7 papers) and Cardiac electrophysiology and arrhythmias (6 papers). Mei Cheng collaborates with scholars based in United States, Austria and United Kingdom. Mei Cheng's co-authors include Thierry H. LeJemtel, William T. Abraham, Kirkwood F. Adams, Janet Wynne, Gregg C. Fonarow, Maria Rosa Costanzo, Robert Berkowitz, Marc A. Silver, Jalal K. Ghali and Andrew J. Burger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Mei Cheng

18 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications

2005 500 citations William T. Abraham, Kirkwood F. Adams et al. Journal of the American College of Cardiology profile →

Peers

Countries citing papers authored by Mei Cheng

Since Specialization

Citations

This map shows the geographic impact of Mei Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei Cheng more than expected).

Fields of papers citing papers by Mei Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei Cheng. The network helps show where Mei Cheng may publish in the future.

Co-authorship network of co-authors of Mei Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Mei Cheng. A scholar is included among the top collaborators of Mei Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei Cheng. Mei Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Global, Regional, and National Burden of Low Back Pain 2025 ·Spine ·Mei Cheng, (unknown), Min Cui, Xianlin Zeng, Yang Cao, Fan Ding, Lin Xie	9
2	Letter to the Editor regarding “Global, Regional, and National Burden of Low Back Pain Findings from the Global Burden of Disease Study 2021 and Projections to 2050” by Cheng et al. 2025 ·Spine ·Mei Cheng, (unknown), Min Cui, Xianlin Zeng, Yang Cao, Fan Ding, Lin Xie	0
3	Evaluating the effectiveness of six exercise interventions for low back pain: a systematic review and meta-analysis 2025 ·BMC Musculoskeletal Disorders ·Mei Cheng, Yu Tian, Qi Ye, Jun Li, Lin Xie, Fan Ding	0
4	Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model 2020 ·Journal of Clinical Oncology ·Inhye E. Ahn, Xin Tian, David Ipe, Mei Cheng, Maher Albitar, L. Claire Tsao, Lei Zhang, Wanlong Ma, Sarah E.M. Herman, Erika M. Gaglione, Susan Soto, James P. Dean, Adrian Wiestner	56
5	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review 2018 ·The Lancet Haematology ·Christian Buske, Shalal Sadullah, Efstathios Kastritis, Alessandra Tedeschi, Ramón García‐Sánz, Łukasz Bołkuń, Xavier Leleu, Wolfgang Willenbacher, Roman Hájek, Monique C. Minnema, Mei Cheng, Elizabeth Bilotti, Thorsten Graef, Meletios Α. Dimopoulos	28
6	Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib 2018 ·Blood ·Inhye E. Ahn, Xin Tian, Maher Albitar, Sarah E.M. Herman, Erika M. Cook, Susan Soto, Wanlong Ma, David Ipe, L. Claire Tsao, Mei Cheng, James P. Dean, Adrian Wiestner	7
7	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib 2017 ·British Journal of Haematology ·Jeffrey A. Jones, Peter Hillmen, Steven Coutré, Constantine S. Tam, Richard R. Furman, Paul M. Barr, Stephen J. Schuster, Thomas J. Kipps, Ian W. Flinn, Ulrich Jaeger, Jan A. Burger, Mei Cheng, Joi Ninomoto, Danelle F. James, John C. Byrd, Susan O’Brien	65
8	Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials 2015 ·Blood ·Peter Hillmen, Graeme Fraser, Jeffrey A. Jones, Simon Rule, Susan O’Brien, (unknown), Ulrich Jaeger, Sebastian Grosicki, Florence Cymbalista, Steven Sun, Joi Ninomoto, Michelle Mahler, Mei Cheng, Joris Diels, Fong Clow, Mariya Salman, Danelle F. James, Angela Howes, Asher Chanan‐Khan	20
9	Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia 2015 ·Blood ·Christian Buske, Shalal Sadullah, (unknown), Giulia Benevolo, Ramón García‐Sánz, Łukasz Bołkuń, Xavier Leleu, Wolfgang Willenbacher, Roman Hájek, Ellen van der Spek, Mei Cheng, Thorsten Graef, Meletios Α. Dimopoulos	3
10	Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib 2014 ·Annals of Hematology ·David Smith, Leanne Goldstein, Mei Cheng, Danelle F. James, Lori Kunkel, Maria Fardis, Ahmed Hamdy, Raquel Izumi, Joseph J. Buggy, Fong Clow	8
11	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy 2014 ·Blood ·Jeffrey A. Jones, Peter Hillmen, Steven Coutré, Constantine S. Tam, Richard R. Furman, Paul M. Barr, Stephen J. Schuster, Thomas J. Kipps, Ian W. Flinn, Ulrich Jaeger, Jan A. Burger, Mei Cheng, (unknown), Danelle F. James, John C. Byrd, Susan O’Brien	13
12	The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine 2012 ·EP Europace ·Ewa Karwatowska‐Prokopczuk, Whedy Wang, Mei Cheng, Dewan Zeng, Peter J. Schwartz, Luiz Belardinelli	32
13	Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial 2012 ·European Journal of Preventive Cardiology ·J. López Sendón, Stella Lee, Mei Cheng, Ori Ben‐Yehuda, (unknown)	19
14	Antithrombotic therapies in patients with heart failure: hypothesis formulation from a research database 2010 ·Pharmacoepidemiology and Drug Safety ·(unknown), Rachel Weinstein, John H. Zhang, Mei Cheng, George E. Griffin, (unknown), Alexei N. Plotnikov, (unknown), Leonard Oppenheimer, Paul Burton	3
15	Hemodynamics, Diuretics, and Nesiritide: A Retrospective VMAC Analysis 2009 ·Clinical Cardiology ·James B. Young, Mei Cheng, Roger M. Mills	6
16	Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure 2008 ·Circulation Heart Failure ·Clyde W. Yancy, Henry Krum, Barry M. Massie, Marc A. Silver, Lynne W. Stevenson, Mei Cheng, (unknown), (unknown)	84
17	The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: Study rationale and design 2007 ·American Heart Journal ·Clyde W. Yancy, Henry Krum, Barry M. Massie, Marc A. Silver, Lynne W. Stevenson, Mei Cheng, (unknown), (unknown)	30
18	In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications breakdown → 2005 ·Journal of the American College of Cardiology ·William T. Abraham, Kirkwood F. Adams, Gregg C. Fonarow, Maria Rosa Costanzo, Robert Berkowitz, Thierry H. LeJemtel, Mei Cheng, Janet Wynne	500
19	Clinical and Hemodynamic Effects of Nesiritide (B‐Type Natriuretic Peptide) in Patients With Decompensated Heart Failure Receiving β Blockers 2005 ·Congestive Heart Failure ·William T. Abraham, Mei Cheng, (unknown)	11
20	Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study 2002 ·American Heart Journal ·Andrew J. Burger, Darlene P. Horton, Thierry H. LeJemtel, Jalal K. Ghali, Guillermo Torre‐Amione, George W. Dennish, Michael Koren, Jay Dinerman, Marc A. Silver, Mei Cheng, Uri Elkayam	217

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact